Gregory Renza
Stock Analyst at RBC Capital
(2.20)
# 2,553
Out of 4,670 analysts
195
Total ratings
38.89%
Success rate
-3.48%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INO Inovio Pharmaceuticals | Maintains: Sector Perform | $7 → $6 | $4.07 | +47.42% | 9 | Nov 15, 2024 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $4 → $2 | $0.16 | +1,144.56% | 8 | Nov 14, 2024 | |
| FULC Fulcrum Therapeutics | Reiterates: Sector Perform | $4 | $3.25 | +23.08% | 3 | Nov 14, 2024 | |
| SPRB Spruce Biosciences | Reiterates: Sector Perform | $2 | $0.48 | +313.82% | 12 | Nov 12, 2024 | |
| PCRX Pacira BioSciences | Maintains: Sector Perform | $15 → $16 | $17.55 | -8.83% | 10 | Nov 7, 2024 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 → $6 | $2.80 | +114.29% | 5 | Nov 7, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $11 → $2 | $0.99 | +101.11% | 7 | Nov 5, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Outperform | $35 | $20.54 | +70.40% | 2 | Nov 1, 2024 | |
| AGIO Agios Pharmaceuticals | Reiterates: Outperform | $55 | $55.68 | -1.22% | 5 | Nov 1, 2024 | |
| EXEL Exelixis | Reiterates: Outperform | $34 | $35.61 | -4.52% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $179 | $126.67 | +41.31% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $4.00 | +225.00% | 8 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $26 | $22.05 | +17.91% | 10 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $25.01 | +35.95% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $362 | $294.53 | +22.91% | 14 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $26.79 | +127.70% | 11 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $66 | $33.47 | +97.19% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $44 | $20.20 | +117.82% | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $27 | $3.47 | +678.10% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $9.96 | -9.64% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $3.03 | +428.05% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $68 | $22.05 | +208.39% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $26 | $16.37 | +58.83% | 15 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.99 | +302.01% | 11 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $18 | $0.19 | +9,373.68% | 7 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $10.13 | +1,676.90% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $2.88 | +2,677.78% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $1.81 | +1,557.46% | 3 | Jun 2, 2020 |
Inovio Pharmaceuticals
Nov 15, 2024
Maintains: Sector Perform
Price Target: $7 → $6
Current: $4.07
Upside: +47.42%
Viracta Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.16
Upside: +1,144.56%
Fulcrum Therapeutics
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.25
Upside: +23.08%
Spruce Biosciences
Nov 12, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $0.48
Upside: +313.82%
Pacira BioSciences
Nov 7, 2024
Maintains: Sector Perform
Price Target: $15 → $16
Current: $17.55
Upside: -8.83%
Nuvation Bio
Nov 7, 2024
Maintains: Outperform
Price Target: $5 → $6
Current: $2.80
Upside: +114.29%
Verrica Pharmaceuticals
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $0.99
Upside: +101.11%
Bicycle Therapeutics
Nov 1, 2024
Reiterates: Outperform
Price Target: $35
Current: $20.54
Upside: +70.40%
Agios Pharmaceuticals
Nov 1, 2024
Reiterates: Outperform
Price Target: $55
Current: $55.68
Upside: -1.22%
Exelixis
Oct 30, 2024
Reiterates: Outperform
Price Target: $34
Current: $35.61
Upside: -4.52%
Oct 23, 2024
Maintains: Outperform
Price Target: $175 → $179
Current: $126.67
Upside: +41.31%
Oct 18, 2024
Reiterates: Outperform
Price Target: $13
Current: $4.00
Upside: +225.00%
Oct 14, 2024
Maintains: Outperform
Price Target: $27 → $26
Current: $22.05
Upside: +17.91%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $25.01
Upside: +35.95%
Sep 26, 2024
Reiterates: Outperform
Price Target: $362
Current: $294.53
Upside: +22.91%
Sep 24, 2024
Reiterates: Outperform
Price Target: $61
Current: $26.79
Upside: +127.70%
Sep 23, 2024
Initiates: Outperform
Price Target: $66
Current: $33.47
Upside: +97.19%
Sep 19, 2024
Reiterates: Outperform
Price Target: $44
Current: $20.20
Upside: +117.82%
Aug 16, 2024
Maintains: Outperform
Price Target: $29 → $27
Current: $3.47
Upside: +678.10%
Aug 15, 2024
Reiterates: Outperform
Price Target: $9
Current: $9.96
Upside: -9.64%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $3.03
Upside: +428.05%
Aug 14, 2024
Maintains: Outperform
Price Target: $70 → $68
Current: $22.05
Upside: +208.39%
Aug 7, 2024
Maintains: Outperform
Price Target: $29 → $26
Current: $16.37
Upside: +58.83%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.99
Upside: +302.01%
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $0.19
Upside: +9,373.68%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $10.13
Upside: +1,676.90%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $2.88
Upside: +2,677.78%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $1.81
Upside: +1,557.46%